Table 3. Follow-up data, according to treatment modality at baselinea
| 3 mo | 12 mo | 24 mo | 36 mo | |
|---|---|---|---|---|
| a Measurements and follow-up times during treatment, according to the modality at 3 mo, were considered [as-treated (AT) censoring]. Values are means and 95% confidence intervals (CI). | ||||
| No. at risk | ||||
| HD | 742 | 572 | 372 | 232 |
| PD | 480 | 357 | 205 | 111 |
| Davies score (intermediate/high) (%) | ||||
| HD | 50.1/11.6 | 49.7/10.5 | 48.9/9.7 | 50.0/11.6 |
| PD | 34.2/7.1 | 34.7/7.6 | 32.7/8.8 | 34.2/4.5 |
| Presence of cardiovascular morbidity (%) | ||||
| HD | 40.8 | 42.3 | 45.4 | 48.7 |
| PD | 25.4 | 26.3 | 28.3 | 25.2 |
| Hemoglobin level (g/dl) | ||||
| HD | 10.7 (10.6 to 10.8) | 11.4 (11.2 to 11.5) | 11.3 (11.2 to 11.4) | 11.3 (11.1 to 11.4) |
| PD | 11.9 (11.8 to 12.1) | 11.9 (11.7 to 12.0) | 11.7 (11.5 to 11.9) | 11.7 (11.4 to 12.0) |
| Albumin level (g/dl) | ||||
| HD | 3.66 (3.62 to 3.69) | 3.72 (3.68 to 3.76) | 3.64 (3.59 to 3.68) | 3.65 (3.59 to 3.71) |
| PD | 3.64 (3.59 to 3.69) | 3.66 (3.60 to 3.71) | 3.62 (3.55 to 3.69) | 3.57 (3.49 to 3.66) |
| SGA (scale of to 7) | ||||
| HD | 5.7 (5.6 to 5.8) | 6.0 (5.9 to 6.1) | 6.1 (6.0 to 6.2) | 6.1 (6.0 to 6.2) |
| PD | 6.2 (6.1 to 6.3) | 6.4 (6.3 to 6.4) | 6.3 (6.2 to 6.4) | 6.3 (6.1 to 6.5) |
| Renal Kt/V (weekly) | ||||
| HD | 0.70 (0.65 to 0.74) | 0.48 (0.44 to 0.53) | 0.34 (0.29 to 0.40) | 0.32 (0.22 to 0.43) |
| PD | 0.82 (0.77 to 0.87) | 0.64 (0.57 to 0.70) | 0.55 (0.47 to 0.63) | 0.53 (0.41 to 0.65) |